glp-1 and binge eating disorder Agonist for Disorder: Evidence Safety Ozempic, Wegovy, Zepbound — and

GLP-1 receptor agonists are known to suppress appetite, which can lead to a reduced intake of essential micronutrients

At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems

Learn the safe version, who should avoid it, and how it compares to actual Ozempic

Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.At this time, these drugs are only legally accessible to clinical trial patients

/PRNewswire/ -- The Vitamin Shoppe, an omni-channel specialty retailer of nutritional products, today announced the launch of Whole Health Rx by The Vitamin...